Abatacept biosimilar - Momenta Pharmaceuticals

Drug Profile

Abatacept biosimilar - Momenta Pharmaceuticals

Alternative Names: M-834

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Momenta Pharmaceuticals
  • Developer Momenta Pharmaceuticals; Mylan
  • Class Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins
  • Mechanism of Action CD80 antigen inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune disorders; Inflammation

Most Recent Events

  • 30 Jun 2017 Momenta Pharmaceuticals appeals the Patent Trial and Appeal Board's decision regarding validity of US patent 8 476 239 to the US Court of Appeals for the Federal Circuit
  • 30 Jun 2017 The US Court of Appeals for the Federal Circuit denies motion filed by Bristol Myers Squibb to dismiss Momenta Pharmaceuticals' appeal in USA
  • 02 May 2017 Momenta Pharmaceuticals completes enrolment in its phase I trial in Healthy volunteers in United Kingdom (NCT02923583)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top